289 | MULTICENTER REAL‐WORLD OUTCOMES OF FRONTLINE POLA‐R‐CHP IN TREATMENT NAÏVE DLBCL
Alex F. Herrera(City of Hope), Hua‐Jay J. Cherng, Yazeed Sawalha(Cleveland Clinic), D. Wallace(University of Rochester), Thomas Lucido(Rutgers, The State University of New Jersey), Adrienne Nedved(Mayo Clinic), Liangyi Chen(Peking University), Muhamad Alhaj Moustafa(Jacksonville College), José María Manzano(City Of Hope National Medical Center), David A. Russler‐Germain(Washington University in St. Louis), Allison M. Bock(Mayo Clinic), Sok Cheon Pak(Charles Sturt University), V. Pizzuti(University of Colorado Boulder), Pallawi Torka(Roswell Park Comprehensive Cancer Center), Heather Rasmussen(University of Washington Medical Center), Birgitta Heyman(University of California San Diego), Michelle Okwali(Memorial Sloan Kettering Cancer Center), Michele Stanchina(Sylvester Comprehensive Cancer Center), Y. Wang(Mayo Clinic), Venkatesh Iyengar(Memorial Sloan Kettering Cancer Center), Sophie Buller(Wellcome/MRC Institute of Metabolic Science), Talal Hilal(WinnMed), Nicole Birrer(University of Utah), Bernard F. Parker(Jacksonville College), Chaitra S. Ujjani(Fred Hutch Cancer Center), Juan Pablo Alderuccio(Sylvester Comprehensive Cancer Center), Youssef Youssef(The Ohio State University), Tushar Jain(University of California San Diego), Gloria Isabel Carvajal Peláez(Universidad de Medellín), Jennifer L. Crombie(Dana-Farber Cancer Institute), Alyssa Gibson(University of Chicago), James B. Rhodes(University of Kansas Medical Center), A. Bahnasy(Mayo Clinic Hospital), M. Masterson(University of Rochester), Arkady Major(University of Manitoba), Perry M. Gould, Jessica Chicola(Memorial Sloan Kettering Cancer Center), Christine Goth(City Of Hope National Medical Center), Peter A. Riedell(University of Chicago), Denisse Montana(University of Miami)
Cited by 2
Related Papers
Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period
|Gastroenterology|2005|1k
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma
|New England Journal of Medicine|2022|457